The NeoADAURA (NCT04351555) trial, investigating the efficacy and safety of neoadjuvant osimertinib in patients with EGFR-mutated resectable NSCLC, is ongoing. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.